Multiply Labs raises $75M for robotic biomanufacturing expansion
Multiply Labs, a San Francisco biotechnology automation company, has raised $75 million in a Series B funding round. The company plans to use the money to expand its robotic manufacturing platform from cell and gene therapies to broader biologics production, including antibodies, viral vectors, and mRNA. The funding aims to support manufacturing capacity, product development, and growth of the engineering, regulatory, and commercial teams as the company moves toward commercial-scale production.
What changed with Multiply Labs' funding
Multiply Labs announced a $75 million Series B round. The investment is intended to grow its robotic manufacturing platform so it can handle broader biologics, not just cell and gene therapies. The company says the systems can automate repetitive manufacturing steps and work inside existing facilities without altering validated processes. The round increases the company’s total fundraising to over $100 million.
Key facts about the funding and platform
- $75 million in Series B financing. — worth weighing when comparing Multiply Labs raises 75M Series B options in Manama.
- Focus:Expand robotic manufacturing from cell and gene therapies to other biologics such as antibodies and viral vectors.
- Platform use:Automates timed, repetitive steps and integrates with current instruments without changing validated processes.
- Scale goal:Move from clinical deployments to commercial-scale production.
- Team impact:Plans to grow engineering, regulatory, and commercial teams.
Who is affected by this development
The funding and platform expansion primarily affect Multiply Labs’ employees (engineering, regulatory, and commercial teams) and its customers in the biotechnology and pharmaceutical manufacturing ecosystem who rely on automated systems for biologics production. It may also influence suppliers and partners involved in automated manufacturing infrastructure, though the article does not detail specific companies beyond Multiply Labs.
Practical next steps and what to watch
- Watch for announcements on new commercial-scale production capabilities and any pilots with partner biopharma producers.
- Look for updates on regulatory milestones if the company begins broader commercial manufacturing under validated processes.
- Follow potential partnerships or tooling updates as the platform expands to new biologics like antibodies or mRNA products.
Limits and questions readers may have
The article summarizes a funding round and stated platform goals but provides limited details on which exact biologics programs will be piloted first, the expected production capacities, or timelines for commercial-scale deployment. No local policy or regional regulatory changes are mentioned in the source text.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- pharmamanufacturing.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.